Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients ≥60 Years With Heart Failure and Reduced Ejection Fraction

American Journal of Cardiology

Volumn 119, Issue 12, 2017, Pages 2042-2048

  Löfsjögård, Johan ^a   Kahan, Thomas ^a   Díez, Javier ^b,c   López, Begoña ^b   González, Arantxa ^b   Ravassa, Susana ^b   Mejhert, Märit ^a,d   Edner, Magnus ^e   Persson, Hans ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d ERSTA HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; COLLAGEN CARBOXY TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COLLAGEN TYPE 1; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I CARBOXY TERMINAL PEPTIDE;

ACUTE HEART FAILURE; AGED; ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CONGESTIVE HEART FAILURE; FEMALE; FOLLOW UP; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEW YORK HEART ASSOCIATION CLASS; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; BIOSYNTHESIS; BLOOD; EPIDEMIOLOGY; FORECASTING; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; SWEDEN; TRENDS;

AGED; BIOMARKERS; COLLAGEN TYPE I; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROGNOSIS; RETROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE; SWEDEN;

EID: 85018286678     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2017.03.036     Document Type: Article

References (26)

1. 1 Weber, K.T., Brilla, C.G., Janicki, J.S., Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 27 (1993), 341–348.
2. 2 Díez, J., López, B., González, A., Querejeta, R., Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 16 (2001), 328–335.
3. 3 Pfeffer, M.A., Pfeffer, J.M., Steinberg, C., Finn, P., Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 72 (1985), 406–412.
4. 4 Pfeffer, M.A., Pfeffer, J.M., Ventricular enlargement and reduced survival after myocardial infarction. Circulation 75 (1987), IV93–IV97.
5. 5 Linde, C., Abraham, W.T., Gold, M.R., St John Sutton, M., Ghio, S., Daubert, C., Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 52 (2008), 1834–1843.
6. 6 Chalikias, G.K., Tziakas, D.N., Biomarkers of the extracellular matrix and of collagen fragments. Clin Chim Acta 443 (2015), 39–47.
7. 7 López, B., González, A., Díez, J., Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 121 (2010), 1645–1654.
8. 8 López, B., González, A., Ravassa, S., Beaumont, J., Moreno, M.U., San José, G., Querejeta, R., Díez, J., Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 65 (2015), 2449–2456.
9. 9 Löfsjögård, J., Kahan, T., Díez, J., López, B., González, A., Edner, M., Henriksson, P., Mejhert, M., Persson, H., Biomarkers of collagen type I metabolism are related to b-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. J Cardiovasc Med 15 (2014), 463–469.
10. 10 Mejhert, M., Kahan, T., Persson, H., Edner, M., Limited long term effects of a management programme for heart failure. Heart 90 (2004), 1010–1015.
11. 11 Schiller, N.B., Shah, P.M., Crawford, M., DeMaria, A., Devereux, R., Feigenbaum, H., Gutgesell, H., Reichek, N., Sahn, D., Schnittger, I., Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 2 (1989), 358–367.
12. 12 Höglund, C., Alam, M., Thorstrand, C., Atrioventricular valve plane displacement in healthy persons. An echocardiographic study. Acta Med Scand 224 (1988), 557–562.
13. 13 Mejhert, M., Linder-Klingsell, E., Edner, M., Kahan, T., Persson, H., Ventilatory variables are strong prognostic markers in elderly patients with heart failure. Heart 88 (2002), 239–243.
14. 14 Mejhert, M., Kahan, T., Edner, M., Persson, H.E., Sex differences in systolic heart failure in the elderly: the prognostic importance of left ventricular mass in women. J Womens Health 17 (2008), 373–381.
15. 15 Waldenhjort, D., Mejhert, M., Edner, M., Rosenqvist, M., Persson, H., Congestive heart failure with and without atrial fibrillation - different patient populations?. Scand Cardiovasc J 43 (2009), 169–175.
16. 16 Nagueh, S.F., Middleton, K.J., Kopelen, H.A., Zoghbi, W.A., Quiñones, M.A., Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30 (1997), 1527–1533.
17. 17 Berg, J., Lindgren, P., Kahan, T., Schill, O., Persson, H., Edner, M., Mejhert, M., Health-related quality of life and long-term morbidity and mortality in patients hospitalised with systolic heart failure. JRSM Cardiovasc Dis, 3, 2014 2048004014548735.
18. 18 Pocock, S.J., Ariti, C.A., McMurray, J.J., Maggioni, A., Køber, L., Squire, I.B., Swedberg, K., Dobson, J., Poppe, K.K., Whalley, G.A., Doughty, R.N., Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 34 (2013), 1404–1413.
19. 19 Zannad, F., Alla, F., Dousset, B., Perez, A., Pitt, B., Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales investigators. Circulation 102 (2000), 2700–2706.
20. 20 Klappacher, G., Franzen, P., Haab, D., Mehrabi, M., Binder, M., Plesch, K., Pacher, R., Grimm, M., Pribill, I., Eichler, H.-G., Glogar, H.D., Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75 (1995), 913–918.
21. 21 Plaksej, R., Kosmala, W., Frantz, S., Herrmann, S., Niemann, M., Störk, S., Wachter, R., Angermann, C.E., Ertl, G., Bijnens, B., Weidemann, F., Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J Hypertens 27 (2009), 2483–2491.
22. 22 Fukui, M., Goda, A., Komamura, K., Nakabo, A., Masaki, M., Yoshida, C., Hirotani, S., Lee-Kawabata, M., Tsujino, T., Mano, T., Masuyama, T., Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure. Heart Vessels 31:2 (2016), 173–182.
23. 23 López, B., Ravassa, S., González, A., Zubillaga, E., Bonavila, C., Berges, M., Echegaray, K., Beaumont, J., Moreno, M.U., San José, G., Larman, M., Querejeta, R., Díez, J., Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol 67 (2016), 251–260.
24. 24 Agarwal, I., Glazer, N.L., Barasch, E., Biggs, M.L., Djousse, L., Fitzpatrick, A.L., Gottdiener, J.S., Ix, J.H., Kizer, J.R., Rimm, E.B., Sicovick, D.S., Tracy, R.P., Mukamal, K.J., Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study. Circ Arrhythm Electrophysiol 7 (2014), 583–589.
25. 25 Hilden, J., Gerds, T.A., A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index. Stat Med 33 (2014), 3405–3414.
26. 26 Aoki, T., Fukumoto, Y., Sugimura, K., Oikawa, M., Satoh, K., Nakano, M., Nakayama, M., Shimokawa, H., Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circ J 75 (2011), 2605–2613.